Is Sugammadex for real ?

Quote

Anonymous

Guest
Just came back from B minus Rah, Rah meeting designed to prepare us to roll out this drug. I have been a hospital rep for over ten years.

I am not convinced hospitals are going to purchase this at 100+ dollars per case ???
 


















Anonymous said:
Just came back from B minus Rah, Rah meeting designed to prepare us to roll out this drug. I have been a hospital rep for over ten years.

I am not convinced hospitals are going to purchase this at 100+ dollars per case ???
Click to expand...

At 100+ per case there must be something wrong with the compound - Merck would NEVER price a drug this low!
 






CRNA here. This drug has a very niched, very specific medical need. Just read the international literature and you will see that its' utilization is quite narrow. It has been on the market for almost 5 years and they are still trying to figure out where to use it. Puzzling why they can not drive any sig data.

Merck is desperate at this point. This is the last of the "promising" agents that SP sold to merck for that whopping 45 billion dollars.

Great job merck, looks like you will be going down 5/5 on that little spend. OMG

Who runs that place anyway ? No wonder most analysts have just down graded the stock.
 






Cases of a hundred? A doc I am friends with that is head of anesthesia said it is a drug that he would use maybe every ten years- once!!! Said its so small a need and then not even a need.
 






Anonymous said:
Cases of a hundred? A doc I am friends with that is head of anesthesia said it is a drug that he would use maybe every ten years- once!!! Said its so small a need and then not even a need.
Click to expand...

that is nonsense...just start to really monitor th eprevailing level of residual block in all patients and consider the potential savings, also the savings from a legal perspective in a defensive medical practice.
Bridion is doing OK ex-US, it takes a little while for anesthesiologists to see its full potential but once experienced they will love it (and use it more often than they are currently thinking)
 






Anonymous said:
that is nonsense...just start to really monitor th eprevailing level of residual block in all patients and consider the potential savings, also the savings from a legal perspective in a defensive medical practice.
Bridion is doing OK ex-US, it takes a little while for anesthesiologists to see its full potential but once experienced they will love it (and use it more often than they are currently thinking)
Click to expand...

What are you talking about? And anesthesia is only a small audience- the big ones are ER, EMS, surge centers etc. Do you have any idea what you are talking about? Has to be the stupidest post I have ever seen. And I am not a rep but a clinician that uses paralytics. I have no idea who you think is going to use this. Full potential ? Of what?
 






Anonymous said:
CRNA here. This drug has a very niched, very specific medical need. Just read the international literature and you will see that its' utilization is quite narrow. It has been on the market for almost 5 years and they are still trying to figure out where to use it. Puzzling why they can not drive any sig data.

Merck is desperate at this point. This is the last of the "promising" agents that SP sold to merck for that whopping 45 billion dollars.

Great job merck, looks like you will be going down 5/5 on that little spend. OMG

Who runs that place anyway ? No wonder most analysts have just down graded the stock.
Click to expand...

You're a CRNA? Your spelling is atrocious. Scary.
 






Anonymous said:
What are you talking about? And anesthesia is only a small audience- the big ones are ER, EMS, surge centers etc. Do you have any idea what you are talking about? Has to be the stupidest post I have ever seen. And I am not a rep but a clinician that uses paralytics. I have no idea who you think is going to use this. Full potential ? Of what?
Click to expand...

Thats what people I have talked to seem to say. They are the treaters and they arent sure why they would need it. Typical merck launch....create a need when it doesnt exist.
 
























Inquiring minds need to know. Utilization of paralytics (non-depolarizing) are used like water where ? ER, Day surgery, Really ?

Regional block, inhaled anesthetics, propofol plus remifentanyl, why the heck would I use roc or vec ?

On another note, when we have to use roc for intubation, or residual NMB rate is virtually zero when you know what you are doing ?

If that is the angle they intend to play, good luck.
 






Talked with numerous KOL's in major institutions: Overall Consensus="No Clinical/Outcome needed basis for this Product" especially in todays Healthcare Enviroment! Anes./Surg. doesnt want it and surely not Pharmacy$$$$!
 






Anonymous said:
Just came back from B minus Rah, Rah meeting designed to prepare us to roll out this drug. I have been a hospital rep for over ten years.

I am not convinced hospitals are going to purchase this at 100+ dollars per case ???
Click to expand...

But, wait, wasn't this one of Fred's 5 shining stars?! I want my money back!!!!!
 






























Top Bottom
Back
Quote